DARYL GAUGLER - 06 Jun 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Operating Officer
Signature: /s/ Kristen Williams, Attorney-in-Fact
Issuer symbol: PCRX
Transactions as of: 06 Jun 2022
Net transactions value: -$67,880
Form type: 4
Filing time: 08 Jun 2022, 19:24:53 UTC
Previous filing: 11 May 2022
Next filing: 02 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Sale	$67,880	-1,106	-8.8%	$61.37	11,494	06 Jun 2022	Direct	F1
transaction	PCRX	Common Stock	Award	$0	+7,900	+69%	$0.000000	19,394	08 Jun 2022	Direct	F2
transaction	PCRX	Common Stock	Award	$0	+5,000	+26%	$0.000000	24,394	08 Jun 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Award	$0	+19,800		$0.000000	19,800	08 Jun 2022	Common Stock	19,800	$59.39	Direct	F3
transaction	PCRX	Stock Option (Right to Buy)	Award	$0	+10,000		$0.000000	10,000	08 Jun 2022	Common Stock	10,000	$59.39	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2	Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F3	The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.